| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WORCESTER, Mass.—RXi Pharmaceuticals, a fully owned subsidiary of CytRx, announced it signed an exclusive licensing deal with Thermo Fisher Scientific for certain RNAi sequences for an undisclosed number of target genes. To be incorporated into RXi's growing portfolio of rxRNA compounds, the sequences will be focused on therapeutic areas such as type 2 diabetes and obesity, neurology, and oncology. Financial terms were not disclosed.
 
The RNAi sequences arose from Thermo Fisher's Dharmacon division, which applied a sequence selection algorithm to generate approximately 100 RNAi sequences per target gene. RXi also has the right to license other RNAi sequences developed at Dharmacon against additional target genes.
 
"Licensing RNAi sequences is consistent with our strategy of building a portfolio of RNAi patents and proprietary rxRNA compounds for the discovery of novel therapeutics," explains Dr. Tod Woolf, RXi president and CEO.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue